JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial

David Erritzøe, Tommaso Barba, Kyle T. Greenway, Roberta Murphy, Jonny Martell, Bruna Giribaldi, Christopher Timmermann, Ashleigh Murphy-Beiner, Michelle Baker-Jones, David Nutt, Brandon Weiss, Robin Carhart-Harris

EClinicalMedicine September 23, 2024 DOI: 10.1016/j.eclinm.2024.102799 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Clinical trial Randomized Double-blind Peer reviewed
Topics	Depression Psilocybin
Keywords	Depression therapy Psychedelic medicine Clinical trials Treatment outcomes Follow-up Ssris Mental health research
Citations	46
Key findings	Psilocybin therapy was as effective as an SSRI in reducing depressive symptoms over the follow-up period.

Abstract

The Alexander Mosley Charitable Trust and by the founding partners of Imperial College London's Centre for Psychedelic Research.

Comparable studies

Other non-randomized and open-label trials on psilocybin for depression, most cited first.

Study	Year	Design	Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression	2016	Open-label feasibility trial	n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression	2017	Open-label trial	n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression	2018	Clinical trial	n = 20
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Patients with major depressive disorder	2021	Open-label study	n = 24
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Individuals diagnosed with moderate to severe, treatment-resistant depression	2017	Open-label study	n = 20

Explore topics

Depression Psilocybin Psychedelic-assisted therapy

By condition and practice

Psilocybin for depression